Several companies across the biopharmaceutical, healthcare, and industrial sectors reported their first quarter 2025 financial results and provided business updates. Notably, CytomX Therapeutics Inc. (CTMX) announced positive interim data from a Phase 1 dose escalation study of its EpCAM antibody drug conjugate candidate CX-2051 in patients with advanced colorectal cancer. The study showed a 28% confirmed response rate overall, increasing to 43% at the 10 mg/kg dose. CytomX also priced a $100 million public offering at $1.30 per share for 76.9 million shares, contributing to a pre-market stock surge of over 130%. Other companies reporting Q1 2025 results include Apogee Therapeutics, Aurinia Pharmaceuticals (AUPH), Dole plc (DOLE), Fortrea (FTRE), Redwire Corporation, Tango Therapeutics (TNGX), Lexeo Therapeutics (LXEO), Akero Therapeutics (AKRO), BioXcel Therapeutics (BTAI), Superior, Agenus (AGEN), ArriVent BioPharma (AVBP), MBX Biosciences (MBX), UroGen Pharma (URGN), and many others. These reports cover a wide range of financial and operational updates, highlighting ongoing progress and milestones within their respective pipelines and business strategies.